NovoCure Warns Of Potential $11 Million Tariff Hit If US Trade Pause Expires In 2025
1. NVCR's Q1 2025 loss of 31 cents beats consensus loss of 46 cents. 2. Sales rose 12% YoY to $155 million, exceeding estimates. 3. Tariff changes could impact NVCR with potential import duties rise. 4. Optune Lua received CE Mark for advanced NSCLC treatments. 5. Active patients on TTFields therapy reached 4,268 globally.